Equine endotoxaemia - A state-of-the-art review of therapy

Australian Veterinary Journal

Volumn 83, Issue 1-2, 2005, Pages 45-50

  Sykes, B W ^a   Furr, M O ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MARION DUPONT SCOTT EQUINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE; EQUUS CABALLUS;

ANTIINFECTIVE AGENT; DIMETHYL SULFOXIDE; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL REHYDRATION SOLUTION;

ANIMAL; ANIMAL DISEASE; ENDOTOXEMIA; HORSE; HORSE DISEASE; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIMETHYL SULFOXIDE; ENDOTOXEMIA; GASTROINTESTINAL AGENTS; HORSE DISEASES; HORSES; INFUSIONS, INTRAVENOUS; REHYDRATION SOLUTIONS;

EID: 21744458868     PISSN: 00050423     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.05.005     Document Type: Article

References (92)

1. Tinker MK, White NA, Lessard P et al. Prospective study of equine colic incidence and mortality. Equine Vet J 1997;29:448-453.
2. Baker SM, Drummond WH, Lane TJ, Koterba AM. Follow-up evaluation of horses after neonatal intensive care. J Am Vet Med Assoc 1986;189:1454-1457.
3. Wilson WD, Madigan JE. Comparison of bacteriologic culture of blood and necropsy specimens for determining the cause of foal septicemia: 47 cases (1978-1987). J Am Vet Med Assoc 1989;195:1759-1763.
4. Grulke S, Olle E, Detilleux J et al. Determination of a gravity and shock score for prognosis in equine surgical colic. J Vet Med 2001;48:465-473.
5. Thoefner MB, Ersboll AK, Jensen AL, Hesselholt M. Factor analysis of the interrelationships between clinical variables in horses with colic. Prev Vet Med 2001;48:201-214.
6. Furr MO, Lessard P, White NA. Development of a colic severity score for predicting the outcome of equine colic. Vet Surg 1995;24:97-101.
7. Parry BW, Anderson GA, Gay CC. Prognosis in equine colic: a comparative study of variables used to assess individual cases. Equine Vet J 1983;15:211-215.
8. Puotunen-Reinert A. Study of variables commonly used in examination of equine colic cases to assess prognostic value. Equine Vet J 1986;18:275-277.
9. Parry BW, Anderson GA, Gay CC. Prognosis in equine colic: a study of individual variables used in case assessment. Equine Vet J 1983;15:337-344.
10. Koterba AM, Brewer BD, Tarplee FA. Clinical and clinicopathological characteristics of the septicaemic neonatal foal: review of 38 cases. Equine Vet J 1984;16:376-382.
11. Brewer BD. Neonatal infection. In: Kosch PC, editors. Equine clinical neonatology. 1st edn. Lea and Febiger, Philadelphia, 1990;295-316.
12. Hunt JM, Edwards GB, Clarke KW. Incidence, diagnosis and treatment of postoperative complications in colic cases. Equine Vet J 1986;18:264-270.
13. French NP, Smith JE, Edwards GB, Proudman CJ. Equine surgical colic: risk factors for postoperative complications. Equine Vet J 2002;34:444-449.
14. Proudman CJ, Smith JE, Edwards GB, French NP. Long-term survival of equine surgical colic cases. Part 2: modelling postoperative survival. Equine Vet J 2002;34:438-443.
15. Baxter GM. Equine laminitis caused by distal displacement of the distal phalanx: 12 cases (1976-1985). J Am Vet Med Assoc 1986;189:326-329.
16. Moore JN, Garner HE, Berg JN, Sprouse RF. Intracecal endotoxin and lactate during onset of equine laminitis: a preliminary report. Am J Vet Res 1979;40:722-723.
17. Leeson MC, Fujihara Y, Morrison DC. Evidence for lipopolysaccharide as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 1994;62:4975-4980.
18. Neumann D, Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002;323:59-72.
19. King JN, Gerring EL. Detection of endotoxemia in cases of equine colic. Vet Rec 1988;123:269-271.
20. Moore JN, Barton MH. An update on endotoxemia. Part 1. Mechanisms and pathways. Equine Vet Educ 1998;10:300-306.
21. van Deventer SJ, Cate JW, Tytgat GN. Intestinal endotoxemia. Clinical significance. Gastroenterology 1988;94:825-831.
22. Moore JN. Recognition and treatment of endotoxemia. Vet Clin N Am Equine Pract 1988;4:105-113.
23. Gathiram P, Wells MT, Raidoo D et al. Portal and systemic plasma lipopolysaccharide concentrations in heat-stressed primates. Circ Shock 1988;25:223-230.
24. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysachharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem 1988;263:13479-13481.
25. Jacob AI, Goldberg PK, Bloom N et al. Endotoxin and bacteria in portal blood. Gastroenterology 1977;72:1268-1278.
26. Ruiter DJ, van der Meulen J, Brouwer A et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Investig 1981;45:38-45.
27. Praaing-van Dalen DP, Brouwer A, Knook DL. Clearance capacity of rat liver Kuppfer, endothelial and parenchymal cells. Gastroenterology 1981;81:1036-1044.
28. Moore JN, White NA, Berg JN et al. Endotoxemia following experimental intestinal strangulation obstruction in ponies. Can J Comp Med 1981;45:330-332.
29. Burrows GE. Escherichia coli endotoxemia in the conscious pony. Am J Vet Res 1971;32:243-248.
30. Burrows GE. Hemodynamic alterations in the anesthetized pony produced by slow intravenous administration of Escherichia coli endotoxin. Am J Vet Res 1970;31:1975-1982.
31. Beadle RE, Huber TL. Blood chemistry changes associated with rapid intravenous administration of Escherichia coli endotoxin in anesthetized ponies. J Equine Med Surg 1977;1:371 -375.
32. Moore JN, Garner HE, Shapland JE, Hatfield DG. Lactic acidosis and arterial hypoxemia during sublethal endotoxemia in conscious ponies. Am J Vet Res 1980;41:1696-1698.
33. Thomas L. Physiologic and pathologic alterations produced by endotoxins of gram negative bacteria. Arch Intern Med 1958;101:452-461.
34. Carroll EJ, Schalm OW, Wheat JD. Endotoxemia in a horse. J Am Vet Med Asscc 1965;146:1300-1303.
35. Burrows GE, Cannon J. Endotoxemia induced by rapid intravenous injection of Escherichia coli in anesthetized ponies. Am J Vet Res 1970;31:1967-1973.
36. Shuster R, Traub-Dargatz J, Baxter G. Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. J Am Vet Med Assoc 1997;210:87-92.
37. Corley K. Fluid therapy for horses with gastrointestinal diseases. In: Smith BP, editor. Large animal internal medicine. 3rd edn. Mosby, St. Louis, 2002:682-694.
38. Moore JN, Morris DD. Endotoxemia and septicemia in horses: experimental and clinical correlates. J Am Vet Med Assoc 1992;200:1903-1914.
39. Bernard GR, Wheeler AP, Russell JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 1997;336:912-918.
40. Semrad SD, Hardee GE, Hardee MM, Moore JN. Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses. Equine Ver J 1987;19:201-206.
41. Semrad SD, Moore JN. Effects of multiple low doses of flunixin meglumine on repeated endotoxin challenge in the horse. Prostaglandins Leukot Med 1987;27:169-181.
42. Moore JN, Garner HE, Shapland JE, Hatfield DG. Prevention of endotoxin-induced arterial hypoxaemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 1981;13:95-98.
43. Templeton CB, Bottoms GD, Fessler JF et al. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ Shock 1987;23:231-240.
44. Ewert KM, Fessler JF, Templeton CB et al. Endotoxin-induced hematologic and blood chemical changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Am J Vet Res 1985;46:24-30.
45. Fessler JF, Bottoms GD, Roesel OF et al. Endotoxin-induced changes in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: Efffects of flunixin meglumine. Am J Vet Res 1982;43:140-144.
46. Bottoms GD, Fessier JF, Roesel OF. Endotoxin-induced hemodynamic changes in ponies: Effects of flunixin meglumine. Am J Vet Res 1981;42:1514-1518.
47. Moore JN, Hardee MM, Hardee GE. Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. Am J Vet Res 1986;47:110-113.
48. King JN, Gerring EL. Antagonism of endotoxin-induced disruption of equine bowel motility by flunixin and phenylbutazone. Equine Vet J (Suppl) 1989;38-42.
49. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202:71-77.
50. Jackman BR, Moore JN, Barton MH, Morris DD. Comparison of the effects of ketoprofen and flunixin meglumine on the in vitro response of equine peripheral blood monocytes to bacterial endotoxin. Can J Vet Res 1994;58:138-143.
51. MacKay RJ, Daniels CA, Bleyaert HF et al. Effect of eltenac in horses with induced endotoxaemia. Equine Vet J (Suppl) 2000;26-31.
52. Bentley AP, Barton MH, Lee MD et al. Antimicrobial-induced endotoxin and cytokine activity in an in vitro model of septicemia in foals. Am J Vet Res 2002;63:660-668.
53. Swank GM, Deitch EA. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J Surg 1996;20:411-417.
54. Morris DD, Whitlock RH, Corbeil LB. Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 1986;47:544-550.
55. Morris DD, Whitlock RH. Therapy of suspected septicemia in neonatal foals using plasma-containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med 1987;1:175-182.
56. Garner HE, Sprouse RF, Lager K. Cross protection of ponies from sublethal Escherichia coli endotoxemia by Salmonella typhimurium antiserum. Equine Pract 1988;10:10-16.
57. Spier SJ, Lavoie JP, Cullor JS et al. Protection against clinical endotoxemia in horses by using plasma containing antibody to an Re mutant E. coli (J5). Circ Shock 1989;28:235-248.
58. Durando MM, MacKay RJ, Linda S, Skelley LA. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921-927.
59. Breen RE, Connell RS, Harrison MW. The effect of dimethyl sulfoxide on endotoxin-induced pulmonary dysfunction: a biochemical and electron microscope study. Ann N Y Acad Sci 1983;411:324-327.
60. Fox RB, Fox WK. Dimethyl sulfoxide prevents hydroxyl radical-mediated depolymerization of hyaluronic acid. Ann N Y Acad Sci 1983;411:14-18.
61. Rosenblum W. Dimethyl sulfoxide effects on platelet aggregation and vascular reactivity in pial microcirculation. Ann N Y Acad Sci 1983;411:110-119.
62. Repine JE, Eaton JW, Anders MW et al. Generation of hydroxyl radical by enzymes, chemicals, and human phagocytes in vitro. Detection with the anti-inflammatory agent, dimethyl sulfoxide. J Clin Investig 1979;64:1642-1651.
63. Saeed SA, Karimi SJ, Suria A. Differential effects of dimethyl sulfoxide on human platelet aggregation and arachidonic acid metabolism. Biochem Med Metab Biol 1988;40:143-150.
64. Barton MH. Use of polymyxin B for treatment of endotoxemia in horses. Compend Contin Educ Pract Vet 2000;1056-1059.
65. Parviainen AK, Barton MH, Norton NN. Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. Am J Vet Res 2001;62:72-76.
66. MacKay RJ, Clark CK, Logdberg L, Lake P. Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am J Vet Res 1999;60:68-75.
67. Wang P, Zheng F, Chaudry IH. Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis. J Trauma 1997;42:429-436.
68. Bacher A, Mayer N, Klimscha W et al. Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 1997;25:795-800.
69. Yang S, Zhou M, Koo DJ et al. Pentoxifylline prevents the transition from the hyperdynamic to hypodynamic response during sepsis. Am J Physiol 1999;277:H1036-1044.
70. Lauterbach R, Pawlik D, Kowalczyk D et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999;27:807-814.
71. Barton MH, Moore JN. Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 1994;44:216-220.
72. Barton MH, Moore JN, Norton N. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 1997;58:1300-1307.
73. Baskett A, Barton MH, Norton N et al. Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:1291-1299.
74. Crisman MV, Wilcke JR, Correll LS, Irby MH. Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. J Vet Pharmacol Ther 1993;16:23-31.
75. Barton MH, Ferguson D, Davis PJ, Moore JN. The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. J Vet Pharmacol Ther 1997;20:487-492.
76. Johnstone IB, Crane S. Hemostatic abnormalities in equine colic. Am J Vet Res 1986;47:356-358.
77. Barton MH, Morris DD, Norton N, Prasse KW. Hemostatic and fibrinolytic indices in foals with presumed septicemia. J Vet Intern Med 1998;12:26-35.
78. Ofosu FA, Hirsh J, Esmon CT et al. Unfractionated heparin inhibits thrombincatalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989;257:143-150.
79. Saba HI, Saba SR, Morelli GA. Effect of heparin on platelet aggregation. Am J Hematol 1984;17:295-306.
80. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
81. Moore BR, Hinchcliff KW. Heparin: a review of its pharmacology and therapeutic use in horses. J Vet Intern Med 1994;8:26-35.
82. Mannel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol 2000;74:141 -161.
83. Fiedler VB, Loof I, Sander E et al. Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992;120:574-588.
84. Opal SM, Cross AS, Kelly NM et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1990;161:1148-1152.
85. Cargile JL. MacKay RJ, Dankert JR, Skelley L. Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of miniature horses given endotoxin. Am J Vet Res 1995;56:1451-1459.
86. Barton MH, Bruce EH, Moore JN et al. Effect of tumor necrosis factor antibody given to horses during early experimentally induced endotoxemia. Am J Vet Res 1998;59:792-797.
87. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-125.
88. Longworth KE, Smith BL, Staub NC et al. Use of detergent to prevent initial responses to endotoxin in horses. Am J Vet Res 1996;57:1063-1066.
89. Staub NC Sr, Longworth KE, Serikov V et al. Detergent inhibits 70-90% of responses to intravenous endotoxin in awake sheep. J Appl Physiol 2001;90:1788-1797.
90. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
91. Welles EG, Prasse KW, Moore JN. Use of newly developed assays for protein C and plasminogen in horses with signs of colic. Am J Vet Res 1991;52:345-351.
92. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367.